Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) reached a new 52-week low during trading on Thursday . The stock traded as low as $9.51 and last traded at $9.54, with a volume of 247828 shares traded. The stock had previously closed at $9.71.
A number of research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research note on Friday, November 8th. Wedbush reissued a "neutral" rating and issued a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. BMO Capital Markets dropped their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a report on Friday, January 10th. Canaccord Genuity Group restated a "buy" rating and set a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Finally, Barclays lowered their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating on the stock in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $51.06.
Check Out Our Latest Research Report on NTLA
The firm has a 50 day moving average price of $13.43 and a two-hundred day moving average price of $18.69. The firm has a market capitalization of $962.48 million, a price-to-earnings ratio of -1.74 and a beta of 1.83.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics's quarterly revenue was down 24.1% on a year-over-year basis. During the same period in the prior year, the company earned ($1.38) EPS. As a group, research analysts forecast that Intellia Therapeutics, Inc. will post -5.11 earnings per share for the current year.
In other news, CEO John M. Leonard sold 26,807 shares of the company's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 28,735 shares of company stock valued at $349,909. 3.20% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the business. Avanza Fonder AB acquired a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $421,000. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Intellia Therapeutics by 125.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock valued at $1,411,000 after buying an additional 67,276 shares in the last quarter. Signal Advisors Wealth LLC lifted its position in shares of Intellia Therapeutics by 59.9% during the 4th quarter. Signal Advisors Wealth LLC now owns 74,158 shares of the company's stock valued at $865,000 after acquiring an additional 27,782 shares during the last quarter. AdvisorNet Financial Inc lifted its position in shares of Intellia Therapeutics by 96.4% during the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company's stock valued at $118,000 after acquiring an additional 4,950 shares during the last quarter. Finally, Green Alpha Advisors LLC acquired a new position in shares of Intellia Therapeutics in the 4th quarter worth $138,000. Institutional investors own 88.77% of the company's stock.
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.